Lupin Limited (LUPIN) — Announcement Announcement
Lupin announced U.S. FDA approval of its biosimilar ranibizumab (Ranluspec™) as an interchangeable product for Lucentis, expanding access to wet age-related macular degeneration and other retinal conditions. The approval covers both vial and pre-filled syringe formats in 0.3 mg and 0.5 mg strengths, marking Lupin's second U.S. biosimilar and reinforcing its biotechnology manufacturing capabilities. This development strengthens Lupin's position in the high-growth U.S. biosimilars market and supports long-term growth in complex biologics.
📄 View Original Announcement (PDF)
About Lupin Limited (LUPIN)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.